A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Jul 2018
At a glance
- Drugs Fasinumab (Primary)
- Indications Back pain; Pain
- Focus Therapeutic Use
- Acronyms FACT CLBP 1
- Sponsors Regeneron Pharmaceuticals
- 29 Jun 2018 This trial has been discontinued in Spain.
- 11 Jun 2018 Planned End Date changed from 23 Jul 2019 to 2 Apr 2019.
- 16 May 2018 Planned End Date changed from 30 Sep 2020 to 23 Jul 2019.